great news! fulaimei^®, china's first long-比较正规的买球软件

中

about us
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
- founded in 1995, hansoh is a leading r&d-driven pharmaceutical company in china.
news
- company news
- media focus
- with the objective of 'creating excellence in china's pharmaceuticals and add momentum to "made in china"',hansoh endeavors to make its own contribution to the “healthy china 2030” master plan.
- with the objective of 'creating excellence in china's pharmaceuticals and add momentum to "made in china"',hansoh endeavors to make its own contribution to the “healthy china 2030” master plan.
products
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
- hansoh is committed to innovation and research in the six therapeutic areas, including cns, oncology, anti-infectives, diabetes, gastrointestinal, and cardiovascular. constantly evolving, hansoh makes every effort to forage itself to be a market-leading and world-renowned pharmaceutical company.
r&d
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
- hansoh has been holding on to the strategy of technology and innovation, and established r&d centers located in lianyungang and shanghai.
services
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate marketing systems
- hansoh pursuits the philosophy of “professional marketing of medical products for benefits of all doctors and patients” to actively carry out national policies and establish innovate
contact us
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.
- hansoh sticks to providing “attractive career opportunities, cohesive corporate culture, continuous learning and incentive mechanism” so that employees can have clear career path for both administrative ranks and technical titles.

news

2019.05.05 size

on may 5, 2019, hansoh’s fulaimei^® (polyethylene glycol loxenatide for injection) (available in 0.5ml:0.1mg and 0.5ml:0.2mg) received nda approval from national medical products administration.

polyethylene glycol loxenatide is a glp-1 receptor agonist. it is a category 1.1 innovative drug, independently developed by hansoh based on long-acting drug proprietary technology, for the treatment of type 2 diabetes. as a result of its molecular structure, polyethylene glycol loxenatide only needs one injection per week to achieve a long-term effect.

back to list

news

hotnews